GlassScriptPhysician profile
Mark Edward Burkard
NPI 1194903971
$10,389.29
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,348 · 2020: $625 · 2021: $2,845 · 2023: $167 · 2024: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $350 · Food and Beverage: $221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $350.00 |
| Food and Beverage | $220.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $8,868.75 | 2019-2021 | |
| Athenex Pharmaceutical Division, LLC | $625.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $496.12 | 2021-2024 | |
| Puma Biotechnology, INC. | $191.50 | 2019-2024 | |
| F. Hoffmann-La Roche Ag | $100.00 | 2019 | |
| Macrogenics, INC. | $96.00 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
7 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Burkard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.